Kara Swisher talks to the ambitious FTC chair about big tech misbehavior, and whether existing laws are enough to take on AI
with the DOJ’s Civil Rights Division and the Consumer Financial Protection Board. I love a statement just as much as anyone else, but what’s the point?The point is to make sure these firms know that the existing laws prohibiting discrimination — each of our agencies has laws, be it the Civil Rights laws, the Equal Credit Opportunity Act — that these laws are going to apply.
So I think this is a broader point where increasingly the distinction between digital and non-digital or tech and non-tech is being blurred as these tools and as these technologies get implemented across business. So if we get a merger of grocery stores, there can be a really significant digital aspect of that merger. Relating to how these companies are using the data.
Brasil Últimas Notícias, Brasil Manchetes
Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.
FTC Poised to Block Amgen’s $27.8 Billion Deal for Horizon TherapeuticsThe Federal Trade Commission is preparing to block Amgen’s $28 billion deal to buy Horizon Therapeutics
Consulte Mais informação »
FTC sues to block Amgen acquisition of Horizon TherapeuticsThe deal was a bid to strengthen Amgen's drug portfolio as it prepares to face several patent expirations for key treatments over the next decade.
Consulte Mais informação »
FTC sues to block $27.8 billion acquisition of Horizon Therapeutics, which has U.S. headquarters in DeerfieldThe suit marks the first time the FTC has tried to stop a pharmaceutical merger in years
Consulte Mais informação »
FTC sues to block Amgen’s $26B deal for HorizonRegulators said the deal would give Amgen unfair leverage to block competition for Horizon medications.
Consulte Mais informação »
FTC sues to stop drugmaker Amgen from completing $27.8 billion dealThe Federal Trade Commission is seeking to block drugmaker Amgen's $27.8 billion deal to acquire Horizon Therapeutics, the regulator's first challenge to a pharmaceutical merger in years.
Consulte Mais informação »
FTC sues to block Amgen’s acquisition of Horizon TherapeuticsDeal could allow Amgen to "entrench the monopoly positions" of two Horizon medications, regulators say.
Consulte Mais informação »